Northeast Ohio’s trusted resource for HIV/AIDS Clinical Trials, Primary Care, and World Class Research

A5377 participant summary

Published April 10, 2019 in Trio A5377: A Phase I, first-in-human, ascending-dose study of a tri-specific broadly neutralizing antibody, in participants living with HIV..

Events in March 2023

M	T	W	T	F	S	S
		1	2	3	4	5
6 N/A: National Week of Prayer for the Healing of AIDS N/A March 6, 2023 Read more	7	8	9	10 N/A: National Women & Girls HIV/AIDS Awareness Day N/A March 10, 2023 Read more	11	12
13	14 6:00 pm: CAB Meeting (2nd Tuesdays) 6:00 pm – 7:30 pm March 14, 2023 Read more	15	16	17	18	19
20 N/A: National Native HIV/AIDS Awareness Day N/A March 20, 2023 Read more	21	22	23	24	25	26
27	28	29	30	31 N/A: International Day of Transgender Visibility N/A March 31, 2023 Read more

Case Dental gets $3.25M NIH grant to support research in oral health & HIV

July 13, 2022 9:54 pm

$3.25M NIH grant to support research in oral manifestations of... Read more →

A5383: ELICIT clinical trial of anti-CMV medication letermovir

April 22, 2022 6:49 pm

ACTG launches A5383, clinical trial evaluating potential immunologic benefits of... Read more →

Coronavirus FAQ: What does endemic mean — and are we there yet?

March 12, 2022 6:17 am

Has the pandemic moved into the endemic phase? from NPR’s... Read more →

Breakthrough HIV reported in injectable PrEP trial; experts say drug still very effective

February 23, 2022 4:48 pm

Injectable PrEP highly successful, despite HIV infections Experts say breakthrough... Read more →

NIH’s Dr. Carl Dieffenbach Discusses Highlights of HIV Cure, Treatment and Prevention Research from CROI 2022

February 18, 2022 11:14 pm

CROI2022 overview w/Dr. Carl Dieffenbach, head of NIAID NIAID director... Read more →